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Abstract
To achieve the elimination of onchocerciasis transmission in all African countries will entail enormous challenges, as
has been highlighted by the active discussion around onchocerciasis intervention strategies and evaluation
procedures in this journal.
Serological thresholds for onchocerciasis elimination, adapted for the African setting, need to be established. The
Onchocerciasis Technical Advisory Subgroup of the World Health Organization is currently developing improved
guidelines to allow country elimination committees to make evidence-based decisions. Importantly, onchocerciasis-
related morbidity should not be forgotten when debating elimination prospects. A morbidity management and
disease prevention (MMDP) strategy similar to that for lymphatic filariasis will need to be developed. This will
require collaboration between the onchocerciasis elimination program, the community and other partners
including primary health and mental health programs.
In order to reach the goal of onchocerciasis elimination in most African countries by 2025, we should prioritize
community participation and advocate for tailored interventions which are scientifically proven to be effective, but
currently considered to be too expensive.
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Background
On April 9th 2019, the World Health Organization
(WHO) launched a global consultation for the 2021–2030
roadmap on neglected tropical diseases [1]. An important
item on this new roadmap is the elimination of onchocer-
ciasis in most endemic countries. Thanks to the efforts of
the Onchocerciasis Control Programme in West Africa
(OCP) and the African Programme for Onchocerciasis
Control (APOC), during the last 30–40 years great pro-
gress has been made towards elimination of onchocercia-
sis as a public health problem in many African foci [2].
However to reach the elimination of transmission in all
African countries will entail enormous challenges, as has
been highlighted by the active discussion around oncho-
cerciasis intervention strategies and evaluation procedures
in this journal [3–6].
Main text
Dadzie et al. in an opinion paper put the question: “Is on-
chocerciasis elimination in Africa feasible by 2025” in per-
spective, based on lessons learnt from both OCP and
APOC [3]. They recognise the success of the Onchocercia-
sis Elimination Program for the Americas in eliminating
onchocerciasis transmission in 4 of 6 endemic countries in
South America, but consider that the adoption of serology-
based criteria for elimination, as used in South America,
has unnecessarily prolonged interventions in many areas
where APOC’s own entomological and parasitological cri-
teria for elimination [2] were possibly met already.
In response, Cupp et al. [4] and Richards et al. [5] main-
tain that the American experience in the fight against on-
chocerciasis provides a wealth of research and technical
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know-how that have already, and would continue to benefit
the African continent. They highlight the strategies of twice
or more rounds of mass drug administration (MDA) of
ivermectin per year, as well as the use of OV16 serology as
a decision tool to stop MDA.
These authors disagree about the appropriateness of
serology-based criteria for evaluating onchocerciasis
elimination in Africa. Indeed, the comparative validity of
parasitological versus serological criteria for stopping
MDA is unknown. WHO stepped away from using skin
snip-based parasitological criteria, in view of its reduced
sensitivity at low parasite levels and its invasiveness. Yet,
the evidence underlying the more recent serological cri-
teria is still rather weak and optimal ELISA protocols
still need to be defined [7]. The WHO Onchocerciasis
Technical Advisory Subgroup (OTS) is in fact working
on the evidence base in order to identify strategies to
help country elimination committees make valid deci-
sions. Evidence-based serological thresholds, adapted for
the African continent, would need to be established.
Monitoring for resurgence of onchocerciasis transmis-
sion will equally be required. The development of a
more sensitive antibody test by integrating multiple bio-
markers of Onchocerca volvulus infection may lead to a
reduction in the number of children to test when asses-
sing elimination thresholds [8].
The contributors to the current discussion all agree
that intensified efforts are needed to achieve the ambi-
tious elimination goal, at least in some areas. APOC had
aimed to achieve elimination in 80% of African countries
by 2025 [9], but today it is unlikely that this target will
be reached with the current onchocerciasis elimination
strategies and available funding. Onchocerciasis-endemic
countries in both Africa and South America show con-
siderable variation in the characteristics of the disease
and transmission dynamics. Therefore interventions
need to be tailored to each onchocerciasis focus.
In hyper-endemic areas with high onchocerciasis-
associated morbidity like onchocerciasis-associated epi-
lepsy (OAE), aggressive strategies such as 6-monthly
MDA with high coverage and complementary vector
control should be deployed, as was the case in northern
Uganda [10]. Such interventions are often considered
too expensive, but may turn out to be cost-effective by
decreasing morbidity and mortality. Moreover, oncho-
cerciasis morbidity is often the driving factor that will
increase community participation and therefore coverage
and ultimate success. In hypo-endemic areas, annual
community-directed treatment with ivermectin (CDTI)
may suffice to stop transmission within 6–8 years, but
emphasis must be laid on achieving ≥85% coverage of
eligible population. The need for tailored interventions
underscores the need for more information, for wider
thinking and continuing investigation into the various
components of this disease complex (e.g. new assess-
ment tests, better understanding of the clinical disease,
reassessing the chemotherapeutic regimes, understand-
ing the clinical and transmission significance of hypo-
endemic areas).
In this debate about onchocerciasis elimination, the
elimination of onchocerciasis-related morbidity should
not be forgotten. It has been suggested that onchocercia-
sis is not a public health problem anymore [1, 3]. This is
evident for many regions, but is definitely not true
throughout Africa [11]. Recent studies highlighted OAE
as a major unrecognised public health problem in many
remote onchocerciasis foci where there is inadequate
ivermectin coverage such as in parts of the Democratic
Republic of Congo [12], Cameroon [13], Tanzania [14]
and South Sudan [15]. This also applies to onchoderma-
titis, which still exists in many endemic locations. As-
sessments of the clinical disease are rarely done in
national onchocerciasis programs [16]. Onchocerciasis
elimination programs in Africa should take into account
OAE and the other clinical presentations of this infec-
tion in their elimination and surveillance strategies, and
a morbidity management and disease prevention
(MMDP) strategy similar to that for lymphatic filariasis
will need to be developed [17, 18]. This will require col-
laboration between the onchocerciasis elimination pro-
gram with other partners including primary health and
mental health programs.
Conclusions
In developing the roadmap towards onchocerciasis elimin-
ation, decision-makers should strive to implement the
most effective strategies (bi-annual CDTI, vector control,
etc.) albeit their relatively higher costs. As was so success-
fully done for human immunodeficiency virus infection,
the person living with the infection should be the focus of
our efforts, not the parasite and not the available budget.
It is important to involve the affected communities and
advocate for tailored, evidence-based interventions. Fi-
nally, we should keep the 2025 target for stopping treat-
ment, but clearly a paradigm shift will be needed.
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